LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Year: 2023
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Fox Chase Cancer Center, Sarah Cannon, Tennessee Oncology, University of California, Los Angeles, Pelotonia, The Ohio State University, Institut Gustave Roussy, LungenClinic Grosshansdorf, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Yale University, Emory University, Winship Cancer Institute, Erasmus MC, European Institute of Oncology, Florida Cancer Specialists & Research Institute, The Netherlands Cancer Institute, Hospital Regional Universitario de Málaga, Institut Paoli-Calmettes, Mirati Therapeutics (United States), Centre Hospitalier Universitaire Vaudois
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Mesothelioma Applied Research Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Yale University, Gilead Sciences, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, Ariad Pharmaceuticals, Celgene, Regeneron Pharmaceuticals, Taiho Pharmaceutical, Yale Cancer Center, Jazz Pharmaceuticals, Society for Immunotherapy of Cancer, Novocure, Les Laboratories Pierre Fabre, Mirati Therapeutics, BeiGene, EQRx, Seagen, Natera, Daiichi-Sankyo, Eisai, Shionogi, European Society for Medical Oncology, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, PharmaMar, Ipsen, Da Volterra, Genentech, Samsung, EMD Serono, Loyola University Chicago Stritch School of Medicine, Merck Sharp and Dohme, Loxo Oncology, Foundation Medicine, Daiichi Sankyo Europe
OpenAlex ID: W4387809577